Drug Profile
Dopamine - BrePco Biopharma
Alternative Names: BCO-001; NeoatriconLatest Information Update: 28 Jul 2023
Price :
$50
*
At a glance
- Originator BrePco Biopharma
- Developer Aspire Health Science; BrePco Biopharma
- Class Antihypotensives; Behavioural disorder therapies; Cardiotonics; Catecholamines; Small molecules
- Mechanism of Action Adrenergic receptor agonists; Dopamine D1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Hypotension
Most Recent Events
- 28 Jul 2023 No recent reports of development identified for preclinical development in Hypotension(In neonates) in United Kingdom (IV, Infusion)
- 04 Jan 2023 BrePco Biopharma expects approval from European Medicines Agency for Hypotension in mid-to late-2023 (BrePco Biopharma website; January 2023)
- 01 Oct 2019 BrePco Biopharma terminates the phase III HIP trial in Hypotension (In Neonates) in Belgium, Canada, Czech Republic, Ireland and United Kingdom due to poor recruitment (NCT01482559)